Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Kilickap S., AK S., Dursun O. U., ŞENDUR M. A. N., Karadurmus N., Demirci U.

Future Oncology, vol.19, no.29, pp.2003-2012, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 19 Issue: 29
  • Publication Date: 2023
  • Doi Number: 10.2217/fon-2023-0014
  • Journal Name: Future Oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.2003-2012
  • Keywords: adverse drug reactions, central nervous system, hyperlipidemia, lorlatinib, lung cancer
  • Hacettepe University Affiliated: Yes


The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor, has demonstrated significant systemic and intracranial activity in both first-line and subsequent-line therapy in ALK-positive NSCLC patients. In this review, general characteristics of lorlatinib, its efficacy in the treatment of ALK-positive NSCLC patients and the safety of lorlatinib, particularly addressing central nervous system adverse events, are discussed. Management of central nervous system adverse events, which seem to be specific to lorlatinib therapy, is outlined.